Learn how AI/ML can be used by pharmaceutical and medical device companies to improve the clinical data review and cleansing process.
The pharma industry undoubtedly gets a bad rap. “Drug companies charge too much.” “They are only in it for themselves.” And it goes on and on. But are these accusations truly justified?
In a recent Forbes opinion piece, John Lechleiter, Chairman, President, and Chief Executive Officer of Eli Lilly, brilliantly debunks the more common myths that have led to general antipathy toward the companies many of us rely on each day.
Read the article here.